Ritsma L, Dey-Guha I, Talele N, et al. Integrin β1 activation induces an anti-melanoma host response. PLoS One. 2017;12(4):e0175300. doi:10.1371/journal.pone.0175300.

Zorrilla-Zubilete MA, Yeste A, Quintana FJ, Toiber D, Mostoslavsky R, Silberman DM. Epigenetic control of early neurodegenerative events in diabetic retinopathy by the histone deacetylase SIRT6. J Neurochem. 2018;144(2):128-138. doi:10.1111/jnc.14243.

Wang H, Pan J-Q, Luo L, et al. NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma. Mol Cancer. 2015;14:2. doi:10.1186/1476-4598-14-2.

Huang X, Zhou G, Wu W, et al. Genome editing abrogates angiogenesis in vivo. Nat Commun. 2017;8(1):112. doi:10.1038/s41467-017-00140-3.

Golfmann K, Meder L, Koker M, et al. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018;37(42):5682-5693. doi:10.1038/s41388-018-0380-3.

Lin GL, Nagaraja S, Filbin MG, Suvà ML, Vogel H, Monje M. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2018;6(1):51. doi:10.1186/s40478-018-0553-x.

Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis. 2010;30(1):35-51. doi:10.1055/s-0030-1247131.

Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009;23(18):2152-65. doi:10.1101/gad.1820109.

Theriault JR, Felts AS, Bates BS, et al. Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway. Bioorg Med Chem Lett. 2012;22(1):76-81. doi:10.1016/j.bmcl.2011.11.077.

Chen S, Xue Y, Wu X, et al. Global microRNA depletion suppresses tumor angiogenesis. Genes Dev. 2014;28(10):1054-67. doi:10.1101/gad.239681.114.